Takashi Kei Kishimoto | Chief Science Officer
Selecta Biosciences Inc

Takashi Kei Kishimoto, Chief Science Officer, Selecta Biosciences Inc

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology.  Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease.  Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim.  Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Appearances:



Day 1 Orphan 14th Nov @ 17:00

Preclinical and clinical development of tolerogenic nanoparticles to mitigate immunogenicity against enzyme and gene therapies for orphan diseases

back to speakers